{
    "Trade/Device Name(s)": [
        "LZI Fentanyl Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "k181159",
    "Predicate Device Reference 510(k) Number(s)": [
        "k161216"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "December 3, 2018",
    "Summary Letter Received Date": "October 25, 2018",
    "Submission Date": "April 26, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Norfentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AU680 automated clinical system analyzer",
        "automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Homogeneous enzyme immunoassay",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Fentanyl Enzyme Immunoassay for qualitative determination of norfentanyl in urine using enzyme immunoassay technology.",
    "Indications for Use Summary": "Qualitative determination of norfentanyl in human urine at 5 ng/mL cutoff for prescription use with automated clinical chemistry analyzers; provides preliminary result, requires confirmatory testing for positive results.",
    "fda_folder": "Toxicology"
}